INSM Insmed
- 26.080
- +0.130+0.50%
Insmed News
Insmed To Present at the BofA Securities Health Care Conference 2024
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024
BRIDGEWATER, N.J., April 25, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases,
Insmed Initiated at Buy by Truist Securities
Insmed Initiated at Buy by Truist Securities
Insmed (INSM.US) was first covered by Truist Securities, which gave it a buy rating, with a target price of $48.00.
Insmed (INSM.US) was first covered by Truist Securities, which gave it a buy rating, with a target price of $48.00.
Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)
Truist Securities Initiates Coverage On Insmed With Buy Rating, Announces Price Target of $48
Truist Securities analyst Nicole Germino initiates coverage on Insmed with a Buy rating and announces Price Target of $48.
Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)
Insmed Is Maintained at Overweight by Barclays
Insmed Is Maintained at Overweight by Barclays
Barclays: Maintaining the Insmed (INSM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $37.00 to $40.00.
Barclays: Maintaining the Insmed (INSM.US) rating, adjusted from an increase to an increase rating, and the target price was adjusted from $37.00 to $40.00.
Barclays Maintains Overweight on Insmed, Raises Price Target to $40
Barclays analyst Leon Wang maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $37 to $40.
What Makes Insmed (INSM) a Lucrative Investment?
Insmed Incorporated's (NASDAQ:INSM) Price Is Out Of Tune With Revenues
With a median price-to-sales (or "P/S") ratio of close to 13.8x in the Biotechs industry in the United States, you could be forgiven for feeling indifferent about Insmed Incorporated's (NASDAQ:INSM) P/S ratio of 12.8x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.
Insmed Is Maintained at Overweight by Wells Fargo
Insmed Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target
Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and maintains $55 price target.
Wells Fargo updates the list of long and short stocks for the second quarter: optimistic about Amazon, bearish Tesla
The Wells Fargo stock team provided a list of high-confidence tactics to go long and short for the second quarter, including 10 stocks to go long (or increase) and 4 to short (or reduce) stocks.
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)
Insmed Incorporated To Present Nine Abstracts From Across Its Respiratory Portfolio At American Thoracic Society 2024 International Conference
Insmed Incorporated To Present Nine Abstracts From Across Its Respiratory Portfolio At American Thoracic Society 2024 International Conference
Insmed to Present New Data From Across Its Respiratory Portfolio at the American Thoracic Society 2024 International Conference
Insmed Incorporated (Nasdaq: INSM) today announced that it will present nine abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024, in San Diego.
Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed's Brensocatib
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
Analysis
Price Target
No Data
